Palomba Emanuele, Castelli Valeria, Renisi Giulia, Bandera Alessandra, Lombardi Andrea, Gori Andrea
Infectious Diseases Unit, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy.
Department of Pathophysiology and Transplantation, University of Milano, Milano, Italy.
Semin Respir Crit Care Med. 2021 Dec;42(6):859-872. doi: 10.1055/s-0041-1733830. Epub 2021 Dec 16.
Influenza is an acute respiratory illness caused by the influenza A, B, and C viruses. It can occur in local outbreaks or seasonal epidemics, with possibility to spread worldwide in a pandemic when a novel strain with significant antigenic differences emerges. During the past years, several new drugs have become available, with different accessibility related to specific countries' approval. We have conducted a review of literature, analyzing the most recent data on efficacy and safety of drugs currently available to treat influenza, with a particular attention toward special populations. Efficacy and safety profile of neuraminidase inhibitors (oseltamivir, zanamivir, laninamivir, peramivir) and recently approved cap-dependent endonuclease inhibitor baloxavir marboxil are reported in literature, but still little information is available about special populations such as critically ill patients and patients with a history of chronic respiratory disease. Moreover, the emergence of strains with reduced or no susceptibility to current drugs is a matter of concern, suggesting the need of constant monitoring of viral variants.
流感是一种由甲型、乙型和丙型流感病毒引起的急性呼吸道疾病。它可呈局部暴发或季节性流行,当出现具有显著抗原差异的新型毒株时,有可能在全球范围内大流行。在过去几年中,有几种新药可供使用,其可及性因特定国家的批准情况而异。我们进行了文献综述,分析了目前可用于治疗流感的药物的最新疗效和安全性数据,特别关注特殊人群。文献报道了神经氨酸酶抑制剂(奥司他韦、扎那米韦、拉尼米韦、帕拉米韦)以及最近获批的帽依赖性核酸内切酶抑制剂巴洛沙韦酯的疗效和安全性概况,但关于重症患者和有慢性呼吸道疾病史的患者等特殊人群的信息仍然很少。此外,对现有药物敏感性降低或不敏感的毒株的出现令人担忧,这表明需要持续监测病毒变异株。